HIM
MRTX

Hillhouse Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Hillhouse Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-725,000
Closed -$2.65M – 64
2017
Q2 		$2.65M Hold
725,000
– – 0.04% 56
2017
Q1 		$3.77M Buy
+725,000
New +$3.97M 0.07% 45

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hillhouse Investment Management's MRTX Position: Q3 2017 in Review

Hillhouse Investment Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2017, closing a stake of 725,000 shares — an estimated $2.65M sold.

Hillhouse Investment Management first reported a position in MRTX in Q1 2017 and held it in 2 quarters. The position peaked at $3.77M in Q1 2017. 49 funds tracked by Wall St. Rank hold MRTX as of Q3 2017.

  • Hillhouse Investment Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Hillhouse Investment Management sold 725,000 Mirati Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $2.65M.
  • Hillhouse Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Hillhouse Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $3.77M in Q1 2017.
  • 49 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Hillhouse Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.